8-K: MannKind Reports Strong Q2 2025 Revenue Growth

MannKind Corporation announced second quarter 2025 financial results, reporting a 6% increase in total revenues and significant progress across its pipeline, including a pediatric sBLA submission for Afrezza.

Summary

• Total revenues for the second quarter of 2025 increased by $4.1 million, or 6%, to $76.5 million compared to $72.4 million in the same period of 2024.
• Year-to-date 2025 revenues increased by $16.2 million, or 12%, to $154.9 million compared to $138.6 million in the same period of 2024.
• Royalties increased by 22% in Q2 2025 to $31.2 million, primarily due to increased net sales of Tyvaso DPI.
• Afrezza commercial product revenue increased by 13% in Q2 2025 to $18.3 million, driven by higher demand, price, and lower sales deductions.
• GAAP net income for Q2 2025 was $0.7 million, or $0.00 earnings per share, a significant improvement from a net loss of $2.0 million, or $0.01 loss per share, in Q2 2024.
• Non-GAAP net income for Q2 2025 was $13.9 million, or $0.05 earnings per share, a slight decrease of 3% from $14.3 million in Q2 2024.
• A supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population was submitted, with a review acceptance decision expected in early 4Q 2025.
• Enrollment for the MNKD-101 global Phase 3 trial (ICoN-1) for NTM lung disease is ahead of schedule, with an interim target of 100 patients expected in early 4Q 2025.
• Plans are in place to initiate a Phase 2 clinical trial for MNKD-201 (Nintedanib DPI) for IPF by year-end 2025.
• Cash, cash equivalents, and investments totaled $201.2 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to strong revenue growth, a significant shift to GAAP net income, and substantial progress across multiple key pipeline programs, including a major sBLA submission and accelerated clinical trial enrollment. While expenses increased and foreign currency loss was noted, these are largely offset by the overall positive operational and strategic advancements.

Positives

• Total revenues increased by 6% in Q2 2025 and 12% year-to-date 2025, demonstrating consistent top-line growth.
• Royalties, primarily from Tyvaso DPI, saw a strong 22% increase in Q2 2025, indicating successful partnership leverage.
• Afrezza commercial product revenue grew by 13% in Q2 2025 due to higher demand and improved pricing dynamics.
• Achieved GAAP net income of $0.7 million in Q2 2025, a significant turnaround from a net loss of $2.0 million in the prior year period.
• Submitted a supplemental Biologics License Application (sBLA) for Afrezza in the pediatric population, a key regulatory milestone.
• Enrollment for the MNKD-101 Phase 3 trial (ICoN-1) is ahead of schedule, accelerating progress in the orphan lung pipeline.
• Planned initiation of a Phase 2 clinical trial for MNKD-201 for IPF by year-end 2025 signals advancement of a new pipeline candidate.
• U.S.-based manufacturing facility mitigates potential tariff exposure for majority of revenue and future pipeline programs.

Negatives

• Collaboration and services revenue decreased by 12% in Q2 2025 due to the net impact of one-time items.
• V-Go net revenue decreased by 8% in Q2 2025 due to lower demand.
• Research and development expenses increased by 16% in Q2 2025, driven by clinical trial enrollment and personnel costs.
• Selling, general and administrative expenses increased significantly by 31% in Q2 2025 due to higher headcount, a new medical science liaison team, and increased Afrezza promotional costs.
• Incurred a $5.4 million loss on foreign currency transactions in Q2 2025, compared to a $0.5 million gain in the prior year, due to Euro exchange rate fluctuations impacting future purchase commitments.

Risks

• Risks associated with developing product candidates.
• Unforeseen delays that may impact the timing of clinical trials and reporting data.
• Risks associated with the regulatory review process.
• Manufacturing risks.
• Other risks detailed in MannKind's filings with the Securities and Exchange Commission (SEC), including under the Risk Factors heading of its most recently filed Quarterly Report on Form 10-Q.

Future Outlook

The company anticipates a review acceptance decision for the Afrezza pediatric sBLA in early 4Q 2025 and expects to achieve the interim enrollment target for the MNKD-101 Phase 3 trial in early 4Q 2025. A decision on the Afrezza labeling update is also expected in 4Q 2025. Furthermore, the company plans to initiate a Phase 2 clinical trial for MNKD-201 by year-end 2025, indicating continued advancement of its pipeline.

Management Comments

• "The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes."
• "In our orphan lung pipeline, we’re encouraged by the robust enrollment progress in the ICoN-1 trial of inhaled clofazimine for NTM lung disease, and we are excited to advance nintedanib DPI into Phase 2 for IPF."

Industry Context

The company operates in the specialized fields of inhaled therapeutic products for endocrine diseases (diabetes with Afrezza) and orphan lung diseases (NTM lung disease with MNKD-101 and pulmonary fibrosis with MNKD-201). Its focus on dry-powder formulations and inhalation devices positions it within the growing market for non-invasive drug delivery systems, particularly for chronic conditions. The continued growth in royalties from Tyvaso DPI, a product for pulmonary hypertension, highlights the potential of its platform technology in severe respiratory conditions, aligning with broader industry trends towards innovative treatments for rare diseases.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards. However, the progress in advancing multiple clinical programs (Afrezza sBLA, MNKD-101 Phase 3, MNKD-201 Phase 2) is indicative of a robust R&D pipeline for a company of its size in the biopharmaceutical sector.
• The shift to GAAP net income in Q2 2025, while modest, suggests improving operational efficiency or revenue leverage compared to prior periods, which is a positive trend in the biotech industry where profitability can be elusive during development phases.

Stakeholder Impact

• Shareholders: Positive financial results and significant pipeline advancements could lead to increased shareholder value.
• Patients: Progress in Afrezza for pediatric use and new treatments for NTM lung disease and IPF offer potential new therapeutic options.
• Employees: Increased headcount and bolstered research capabilities indicate growth and investment in human capital.
• Customers: Higher demand for Afrezza suggests positive customer reception and potential for broader adoption.

Next Steps

• Expected review acceptance decision for Afrezza sBLA in pediatric population in early 4Q 2025.
• Expected achievement of interim enrollment target of 100 patients in the ICoN-1 trial for MNKD-101 in early 4Q 2025.
• Expected decision from FDA regarding application to update Afrezza labeling for initial conversion dose in 4Q 2025.
• Plan to initiate Phase 2 clinical trial for MNKD-201 for IPF by year-end 2025.
• Presentation of topline results from the full Afrezza pediatric study (INHALE-1) at a medical meeting in 2H 2025.

Key Dates

Recommendation

The company demonstrates strong operational momentum with a 6% increase in Q2 2025 revenues and a significant shift to GAAP net income. Key pipeline advancements, including the submission of Afrezza's pediatric sBLA, ahead-of-schedule enrollment for a Phase 3 trial (MNKD-101), and planned initiation of a Phase 2 trial (MNKD-201), indicate a robust and progressing product portfolio. While expenses have increased, these are largely investments in future growth. The overall trajectory suggests a positive outlook for long-term value creation.

Keywords

MannKind, MNKD, Afrezza, insulin, diabetes, NTM lung disease, pulmonary fibrosis, inhaled therapeutics, biopharmaceutical, clinical trials, FDA, sBLA, financial results, orphan lung disease, Tyvaso DPI